

1 **Role of sociodemographic, clinical, behavioral, and molecular factors in precision**
2 **prevention of type 2 diabetes: a systematic review**

3 Dhanasekaran Bodhini,¹ Robert W. Morton,^{2,3} Vanessa Santhakumar,⁴ Mariam Nakabuye,⁵
4 Hugo Pomares-Millan,^{6,7} Christoffer Clemmensen,⁵ Stephanie L. Fitzpatrick,⁸ Marta Guasch-
5 Ferre,^{5,9} James S. Pankow,¹⁰ Mathias Ried-Larsen,^{11,12} Paul W. Franks,^{3,9,13,14} ADA/EASD
6 Precision Medicine in Diabetes Initiative, Deirdre K. Tobias,^{4,9*} Jordi Merino,^{5,15*}
7 Viswanathan Mohan,^{1,16*} Ruth J.F. Loos^{5,16*}

8

9 *These authors contributed equally

10

11 **Affiliations:**

12 ¹ Madras Diabetes Research Foundation, Chennai, India.

13 ² Department of Pathology & Molecular Medicine, McMaster University, Hamilton, Canada
14 and Population Health Research Institute, Hamilton, Canada.

15 ³ Department of Translation Medicine, Novo Nordisk Foundation, Hellerup, Denmark

16 ⁴ Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital
17 and Harvard Medical School, Boston, MA, USA.

18 ⁵ Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and
19 Medical Sciences, University of Copenhagen, Denmark.

20 ⁶ Department of Clinical Sciences, Genetic and Molecular Epidemiology Unit, Lund
21 University, Skåne University Hospital Malmö, Malmö, Sweden.

22 ⁷ Department of Epidemiology, Geisel School of Medicine at Dartmouth, Hanover, NH, USA.

23 ⁸ Institute of Health System Science, Feinstein Institutes for Medical Research, Northwell
24 Health, Manhasset, NY, USA.

25 ⁹ Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, US.

26 ¹⁰ Division of Epidemiology and Community Health, School of Public Health, University of
27 Minnesota.

28 ¹¹ Centre for Physical Activity Research, Rigshospitalet.

29 ¹² Institute for Sports and Clinical Biomechanics, University of Southern Denmark.

30 ¹³ Lund University Diabetes Centre, Department of Clinical Sciences, Lund University,
31 Malmö, Sweden.

32 ¹⁴ Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of
33 Medicine, University of Oxford, Oxford, UK.

34 ¹⁵ Diabetes Unit and Center for Genomic Medicine, Massachusetts General Hospital, Boston,
35 MA, USA.

36 ¹⁶ Dr. Mohan's Diabetes Specialities Centre, Chennai, India.

37 ¹⁷ Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount
38 Sinai, New York, NY
39

40 **Correspondence:**

41 **Ruth J.F. Loos**

42 University of Copenhagen

43 Faculty of Health and Medical Sciences

44 Novo Nordisk Foundation Center for Basic Metabolic Research

45 Blegdamsvej 3b

46 N-2200 Copenhagen

47 Denmark

48 Email: ruth.loos@sund.ku.dk

49 ORCID ID: 0000-0002-8532-5087

50

51 **Acknowledgment**

52 We thank Hugo Fitipaldi, Esther González-Padilla, Alisha Sha, and Jiaxi Yang for attending
53 some of the working group meetings and/or for reviewing some of the abstracts.

54

55 The *Precision Medicine in Diabetes Initiative* (PMDI) was established in 2018 by the
56 American Diabetes Association (ADA) in partnership with the European Association for the
57 Study of Diabetes (EASD). The ADA/EASD PMDI includes global thought leaders in
58 precision diabetes medicine who are working to address the burgeoning need for better
59 diabetes prevention and care through precision medicine [Nolan et al, Diabetes Care, 2022].

60 This Systematic Review is written on behalf of the ADA/EASD PMDI as part of a
61 comprehensive evidence evaluation in support of the 2nd International Consensus Report on
62 Precision Diabetes Medicine [Tobias et al, Nat Med year?].

63 **Abstract**

64 The variability in the effectiveness of type 2 diabetes (T2D) preventive interventions
65 highlights the potential to identify the factors that determine treatment responses and those
66 that would benefit the most from a given intervention. We conducted a systematic review to
67 synthesize the evidence to support whether sociodemographic, clinical, behavioral, and
68 molecular characteristics modify the efficacy of dietary or lifestyle interventions to prevent
69 T2D. Among the 80 publications that met our criteria for inclusion, the evidence was low to
70 very low to attribute variability in intervention effectiveness to individual characteristics such
71 as age, sex, BMI, race/ethnicity, socioeconomic status, baseline behavioral factors, or
72 genetic predisposition. We found evidence, albeit low certainty, to support conclusions that
73 those with poorer health status, particularly those with prediabetes at baseline, tend to
74 benefit more from T2D prevention strategies compared to healthier counterparts. Our
75 synthesis highlights the need for purposefully designed clinical trials to inform whether
76 individual factors influence the success of T2D prevention strategies.

77

78 INTRODUCTION

79 Diabetes affects over 530 million people worldwide.¹ Around 90% of all diabetes is estimated
80 to be type 2 diabetes (T2D), a non-autoimmune condition with marked pathophysiological
81 heterogeneity.² In many cases, weight loss interventions have demonstrated to delay
82 progression,³⁻⁶ yet T2D remains a major cause of morbidity and mortality globally.⁷ Chronic
83 inadequate control of hyperglycemia causes downstream microvascular and macrovascular
84 complications that drive the costly and debilitating T2D public health burden.⁷ Coupled with
85 its increasing incidence, public health, and clinical efforts need to optimize effective
86 upstream strategies for T2D prevention.

87 Landmark randomized intervention trials have demonstrated the effectiveness of intensive
88 lifestyle interventions and glucose-lowering drug therapies for delaying the onset of T2D in
89 patients at high risk.³⁻⁶ However, T2D incidence has only escalated in the decades since,
90 despite the success of early clinical trials. It is unclear what underscores the underwhelming
91 scalability and translation of effective prevention strategies in real-world settings, and
92 precision prevention research may contribute to understanding this gap.

93 Precision prevention of T2D serves to minimize an individual's T2D risk factor profile and
94 maximize the effectiveness of new or established strategies for disease prevention,⁸ through
95 targeting of biological interactions and/or removal of barriers to access and adherence to
96 lifestyle modifications. For example, precision prevention approaches might use clinical (e.g.,
97 age, sex, body mass index [BMI]), social (e.g., education attainment, socioeconomic status),
98 or molecular (e.g., genetic, 'omic traits) characteristics to inform strategies likely to elicit the
99 most effective or sustainable response for an individual, resulting in tailored prevention
100 strategies.⁸⁻¹⁰

101 The purpose of this systematic review is to critically appraise the accumulated experimental
102 evidence underpinning the feasibility and effectiveness of the clinical translation of precision
103 prevention of T2D. The scope of our investigation included studies reporting the effect
104 modification of lifestyle, dietary, and other behavioral interventions for T2D prevention by any

105 of the following individual-level factors, including sociodemographics, clinical risk factors,
106 behavior, or molecular traits. This work was undertaken as part of a series of systematic
107 reviews conducted by the ADA/EASD Precision Medicine in Diabetes Initiative, an
108 international collaboration of global leaders in precision diabetes medicine.¹¹
109

110 **METHODS**

111 The systematic review protocol was pre-registered on the International Prospective Register
112 of Systematic Reviews (PROSPERO; CRD42021267686)

113 **Data sources and search**

114 Our search included MEDLINE, Embase, and Cochrane Central Register of Controlled Trials
115 databases for studies reporting on the efficacy of lifestyle or behavioral interventions with
116 T2D incidence, published from 1/1/2000 to 7/15/2021. An experienced librarian developed a
117 search strategy (**Supplement Table 1**), which included combinations of keywords related to
118 behavioral intervention for preventing T2D (diet, lifestyle, physical activity, body weight),
119 study design, and health outcome, and was limited to the English language. We also
120 scanned the references of included manuscripts and the reference list of systematic reviews
121 published within the past two years to identify additional relevant studies.

122 **Study Selection**

123 We included studies reporting the effect of a lifestyle, diet, or other behavioral interventions
124 vs. other active comparators or control on the incidence of T2D and reporting the results
125 stratified by any eligible factor. Eligible interventions of interest included lifestyle or
126 behavioral interventions, ranging from education on a single factor to intensive multi-
127 component modification programs, weight loss, diet or supplementation, and physical
128 activity. Eligible stratification factors, or effect modifiers, included individual-level
129 sociodemographic (i.e., race/ethnicity, socioeconomic status/ education, location, age, sex),
130 clinical factors (i.e., BMI, dysglycemia, presence of comorbidities), behavioral (i.e., baseline
131 diet, physical activity) or molecular traits (i.e., genetics, metabolites). We did not review
132 population-level exposures such as built environment, pollution, or climate. Off-label
133 pharmaceutical interventions and bariatric surgery were beyond the scope of the review. We
134 included non-randomized and randomized clinical studies delivering an eligible intervention,
135 comparing against another active intervention, usual care, placebo control or non-control
136 group. We limited inclusion to studies in adults aged >18 years and enrolling at least 100.

137 Studies exclusively among individuals with a current or history of gestational diabetes were
138 excluded because they overlapped in scope with another PMDI consortium review.

139 **Screening, data extraction, and quality assessment**

140 We used the Covidence online systematic review platform¹² for literature screening, data
141 extraction, and consensus. Screening consisted of two stages: [1] title and abstract and [2]
142 full text. At each screening stage, two independent reviewers determined the eligibility of the
143 citation, and in the case of disagreement, a third reviewer resolved the discrepancy. Among
144 the full papers accepted for inclusion in the review, two independent reviewers extracted
145 detailed information on the study design, participant characteristics, interventions and
146 comparators, effect modifiers, follow-up for T2D, and analytic approach. We extracted
147 findings related to effect modification of treatment vs. comparator on T2D risk, including
148 strata-specific treatment groups' T2D cases and incidence rates, or strata-specific treatment-
149 comparator incidence rate ratios, relative risks, risk differences, etc., including measures of
150 variance. We also recorded results for tests for heterogeneity or interaction of the effect
151 modifier with the intervention effect on T2D and noted any text referring to tests performed
152 with "data not shown". We developed and piloted the data extraction template (**Supplement**
153 **Table 2**) and discrepancies were ruled on by a third reviewer.

154 We evaluated the studies' risk of bias using a modified JBI Critical Appraisal Checklist for
155 randomized controlled trials,¹³ performed by two independent reviewers and disagreements
156 resolved by a third reviewer. We modified the 13-item checklist to 9 questions tailored to
157 evaluating the quality of the study design, but with consideration for our primary interest in
158 stratified results rather than the total intervention effect for T2D risk. These 9 questions were
159 mainly based on randomization, interventions, treatment, and assessor blindness to
160 outcome assessment and our evaluation of these corresponded to color coding in a heat
161 map organized by intervention type and effect modifier (**Supplement Figure 1**).

162 **Synthesis of results**

163 We collated the literature according to intervention type (e.g., lifestyle programs, dietary
164 supplements) and effect modifier analyzed (e.g., sex, age strata) for the synthesis of results.
165 We determined that a meta-analysis was not feasible among the studies included in our
166 review due to paucity and marked differences in the nature of the study populations,
167 interventions and comparators, and study designs, and effect modifiers analyzed. We
168 qualitatively evaluated the direction and magnitude of results and statistical tests among
169 each prevention strategy for each effect modifier. We weighed these qualitative and
170 quantitative results against their risk of bias and derived the certainty of the collective
171 evidence for an effect modifier's influence on an intervention strategy, guided by the
172 Diabetes Canada cClinical Practice Scale.¹⁴ Two reviewers, independently, assessed the
173 certainty of the evidence and resolved disagreements through consensus discussion.

174

175

176 **RESULTS**

177 The results of our systematic literature search are presented in the **Figure 1** attrition
178 diagram. Of the 10,880 citations identified through database searches and other sources,
179 1,047 abstracts were retrieved for full-text review. From these, 80 publications met our
180 inclusion criteria and data were extracted.

181 **Study characteristics**

182 The 80 publications included in our review represented 33 unique intervention studies (**Table**
183 **1, Supplement Table 3**). Twenty-eight studies were randomized clinical trials (RCTs), three
184 studies were nonrandomized parallel group trials, and two studies were single-arm clinical
185 interventions. Fourteen intervention studies took place in Asia, 11 in Europe, seven in North
186 America, and one was a multicenter study that took place in Asia and Europe. Intervention
187 enrollment sample sizes ranged from 302 to 48,835 participants (**Table 1**). Twenty-two
188 studies included individuals at high risk for T2D, two studies at increased cardiovascular risk,
189 and other studies included the general population or other specific groups. The active
190 intervention times ranged from one single lifestyle counseling visit to active interventions
191 lasting up to 10 years (**Supplement Figure 2**).

192 Twenty-four of the included studies assessed the effect of a multi-component lifestyle
193 intervention program, focused on changes in diet, physical activity, smoking, or body weight
194 loss. Four studies implemented a dietary intervention, and five administered supplements.
195 Across multi-component lifestyle intervention studies, the comparator consisted of a less
196 intensive lifestyle program consisting of usual care or general lifestyle advice administered at
197 baseline. Active comparator groups for dietary intervention studies that focused on high-fat
198 diets consisted of a low-fat intervention. The active comparator for supplement studies
199 consisted of a placebo intervention. T2D was diagnosed in-person with an oral glucose
200 tolerance test (OGTT) in 27 studies, whereas in 6 studies, T2D was ascertained via self-
201 report or through linkage with a healthcare registry database. The primary endpoint was T2D

202 incidence in 21 studies or a composite cardiovascular event in six studies (**Table 1,**
203 **Supplement Table 3**).

204 All except seven studies consisting of a multi-component lifestyle intervention program
205 showed evidence that a lifestyle intervention reduces the risk of T2D, with estimated relative
206 risk reduction ranging from 60% to 23% (**Supplement Table 3**). Available evidence also
207 suggests that a high-fat diet, compared to a low-fat diet, reduces the relative risk of T2D.
208 Evidence from studies using supplements showed a null effect on T2D risk reduction.

209 Our risk of bias assessment determined that the primary study design and approach was
210 generally low, particularly for the RCTs, owing to randomization methods and uniform
211 outcome assessment (**Supplement Figure 1**). However, common concerns for bias were
212 due to non-blinding of participants, deliverers, and outcomes assessors to treatment
213 assignment. Nonrandomized interventions and RCTs having additional concerns for study
214 design did have ratings of high risk of bias.

215 **Sociodemographic and clinical factors**

216 Some clinical trials, such as the Diabetes Prevention Program (DPP), the Finnish Diabetes
217 Prevention Study (DPS), or the PREDIMED study, were highly represented, with 20, 16, and
218 6 different publications from each study, respectively. Evidence presented in studies
219 investigating the effect of a lifestyle intervention according to differences in
220 sociodemographic and clinical characteristics did not indicate statistically different effects for
221 age, sex, race/ethnicity, or socioeconomic status. Evidence from studies investigating
222 sociodemographic interaction effects in dietary modification or supplementation trials
223 showed no significant heterogeneity in response to intervention according to these
224 characteristics (**Table 2, Figure 2**).

225 Fourteen studies investigated whether BMI modified the efficacy of multi-component lifestyle
226 interventions. Nine of these studies showed that BMI is not associated with different
227 responses to a lifestyle program, but five studies showed suggestive evidence that

228 individuals with low BMI could benefit most from a lifestyle intervention. Among these five
229 studies presenting evidence of the differential effect of a lifestyle intervention according to
230 BMI, four were conducted in Asia (**Table 3**). No appreciable evidence for interactions with
231 BMI was observed in studies that implemented a dietary or supplement intervention (**Table**
232 **3**). Eighteen studies tested the efficacy of an intensive lifestyle intervention for preventing
233 T2D stratified based on baseline glucose levels, impaired glucose tolerance, or prediabetes
234 status. Evidence presented in eight of these studies indicated statistically different effects
235 based on baseline dysglycemia, but other studies did not find evidence of effect
236 modifications. Three studies investigated family history of T2D as a potential lifestyle
237 intervention effect modifier, and only one provided suggestive evidence of heterogenous
238 treatment responses. Studies stratified by baseline cardiometabolic risk factors reported that
239 individuals with poorer health status, particularly those with dyslipidemia and metabolic
240 syndrome, tend to benefit more from dietary or supplement interventions than individuals
241 who are healthier (**Table 3**).

242 **Behavioral factors**

243 Several secondary studies have assessed whether baseline lifestyle factors (i.e., overall
244 dietary quality, alcohol intake, physical activity, and/or smoking) influence the efficacy of T2D
245 prevention interventions. Evidence presented in studies investigating the effect of a lifestyle
246 intervention according to baseline smoking status and physical activity indicates statistically
247 different effects, suggesting that smokers and those with lower levels of physical activity
248 benefited less from a lifestyle program (**Table 4**). Available studies reported no interactions
249 of baseline smoking status and physical activity levels with dietary or supplement
250 interventions on the risk of T2D. Among the four studies that focused on alcohol intake, only
251 one found that the lifestyle intervention was more effective in individuals who drink alcohol
252 frequently than in those who rarely drink. Six studies tested whether baseline diet modified
253 the association between supplements and the risk of T2D and found no evidence of
254 significant interactions (**Table 4**).

255 **Molecular factors**

256 The extent to which genetic predisposition modifies the efficacy of interventions to prevent
257 T2D was reported in 21 publications, and most of them were based on data from the DPP
258 and the DPS. Genetic predisposition was defined based on single genetic variants in 16
259 studies or genetic risk scores in five studies. While many of the T2D-associated loci
260 identified in the earlier GWAS studies have been examined for their potential roles as effect
261 modifiers, some reported evidence that individuals with specific genotypes could benefit the
262 most from a lifestyle intervention, but these studies rarely corrected for the number of
263 performed tests. Of the five studies that reported on the role of polygenic scores for T2D,
264 only one study showed that lifestyle intervention was more effective among individuals with a
265 high genetic risk.

266 Besides genetics, other molecular markers have also been studied for their potential effect
267 modification of prevention interventions. A posthoc analysis in the PREDIMED trial showed
268 that higher levels of plasma branched-chain amino acid levels at baseline attenuated the
269 beneficial effect of a Mediterranean diet for the prevention of T2D, but these findings have
270 been not replicated in independent studies. A separate study has found that individuals with
271 low plasma levels of miR-29a, miR-28-3p, miR-126 and high plasma levels of miR-150 have
272 a higher risk of developing T2D if they are allocated to a MedDiet, but not if they consume a
273 low-fat and high-carbohydrate diet. (**Table 5, Figure 2**).

274 **Grading of evidence certainty**

275 Although our systematic review included intervention studies, most of which were RCTs with
276 low risk of bias, we evaluated certainty through our hypothesis of identifying valid effect
277 modifiers to inform precision prevention. None of the studies included *a priori* consideration
278 of intervention interactions with individual-level characteristics or risk factors in their study
279 design, which were largely conducted as posthoc analyses. As a result, statistical power was
280 often limited. Further, most did not adjust for individual-level risk factors, undermining validity

281 of interpreting the role of effect modifiers independent of other traits. These considerations
282 were factored into the major downgrading of the evidence (**Tables 2-5**)

283

284 **DISCUSSION**

285 We performed a comprehensive systematic review to identify individual-level
286 sociodemographic, clinical, behavioral, or molecular factors that could modify the efficacy of
287 T2D prevention strategies. Overall, we find low to very low certainty of evidence that traits
288 such as age, sex, BMI, race/ethnicity, socioeconomic status, baseline lifestyle factors, or
289 genetics consistently and validly modify the effectiveness of lifestyle and behavioral
290 interventions. Low-certainty evidence was observed for health status at baseline; individuals
291 with poorer health, particularly those with prediabetes, were likely to benefit from prevention
292 strategies compared to individuals in better health. However, whether the modest benefit
293 reported in these studies was due to poor health status or other correlated risk factors
294 cannot be ascertained based on the available evidence.

295

296 Large randomized clinical trials have consistently demonstrated that a healthy lifestyle or
297 dietary interventions can prevent or delay T2D.^{3,4,6,15} However, there is large inter-individual
298 variability in response to these preventive interventions, in which some people seem to
299 greatly benefit from T2D preventive interventions. Precision prevention aims to identify
300 participant characteristics that determine this variability in response to ultimately tailor
301 preventive strategies to subgroups of individuals that are likely to benefit the most. So far, no
302 studies exist that were prospectively designed to determine interactions by a baseline trait or
303 factor with an intervention in prevention of T2D. We evaluated the evidence base and
304 identified several stratified posthoc analyses of existing prevention intervention trials. In
305 posthoc analyses, the participant population is stratified by a potential effect modifier, and
306 the efficacy of the intervention is tested within each stratum and compared across the strata,
307 which reduces statistical power and increases type 2 error. Furthermore, precision

308 prevention strategies may be optimized by incorporating several individual-level factors into
309 decision making, whereas the current literature is predominantly evaluating one stratified
310 trait as a time. For example, correlated behaviors such as physical activity, diet, and
311 smoking, might provide more information when considered collectively than on their own.
312 Clinical trials specifically designed to investigate the influence of sociodemographic, clinical,
313 behavioral, or molecular factors on the response to T2D preventive strategies are needed to
314 generate valid and robust evidence before the implementation of T2D precision prevention
315 strategies.

316

317 One area of promise warranting further research is the presence of prediabetes at baseline
318 and whether this may be targeted in future precision prevention research. Low certainty
319 evidence suggests that individuals at risk of T2D or with prediabetes at baseline benefit
320 slightly more of prevention interventions than individuals who are not at risk of T2D.³⁻⁶
321 However, the evidence is inconsistent, even though the studies report that a lifestyle
322 intervention, compared to standard care, results in higher T2D reduction rates among
323 studies conducted in Asia.¹⁵⁻¹⁸ Beyond the methodological limitations of the available
324 evidence, an additional reason for inconsistent evidence supporting the greater effectiveness
325 of lifestyle interventions for the prevention of T2D among individuals with prediabetes is due
326 to the heterogeneity that characterizes this condition. Prediabetes refers to a
327 pathophysiological state of early alterations in glucose metabolism that precedes the
328 development of diabetes, but the mechanism by which glucose is elevated are very different
329 and could range from those with primary alterations in insulin secretion pathways to those
330 with primary insulin resistance.¹⁹ Clinical trials specifically designed to capture the nuances
331 and complexity of early glycemic alterations and whether individuals with distinct
332 pathophysiological features benefit from more targeted preventive interventions are needed
333 to fill the gap in current T2D precision prevention evidence.

334

335 Even though there are far more lifestyle intervention trials for the prevention of T2D than diet
336 alone and diet supplementation trials, collectively, however, results for effect modification by
337 any one factor are sparsely reported or arising from an evidence base of very different trials
338 and patient populations. Further, many of the secondary analyses included in this systematic
339 review are derived from two single clinical interventions. Findings from available evidence
340 contrast with recent clinical studies documenting variable responses to identical foods, diets,
341 or lifestyle interventions based on inter-individual differences in demographic, clinical,
342 genetic, gut microbiota, and lifestyle characteristics.^{20–22} While these studies offer insights
343 into variable postprandial metabolic response, their short follow-up periods, the lack of time-
344 series data and changes in parameters that could influence response to interventions, and
345 the inclusion of relatively young and healthy individuals preclude the generalizability to T2D
346 prevention efforts. Whether the promise of T2D precision prevention is matched by evidence
347 of the long-term beneficial impact remains uncertain. Still, interest and activity in this field are
348 proliferating to identify factors underlying variable nutritional responses and develop
349 algorithms to predict individual responses to nutrients, foods, and dietary patterns.

350

351 Our systematic review had some limitations. The scope of our literature review as part of the
352 PDML was broad and inclusive of diverse study designs, T2D prevention strategies, study
353 populations, and effect modification analyses. Although this resulted in a heterogeneous
354 evidence base and did not provide an opportunity for meta-analysis, we qualitatively
355 synthesized the evidence for precision prevention generally. Our hypothesis originally
356 spanned to include observational studies, which were ultimately excluded due to the
357 uncertainty of their being readily related to clinical interventions. Protocol amendments were
358 registered to reflect these decisions prior to study screening and extraction.

359

360 In conclusion, our systematic review and synthesis of the T2D prevention literature provide
361 low to very low certainty evidence that sociodemographic, clinical, lifestyle, or molecular

362 factors are more useful, valid, and consistent in informing T2D precision prevention
363 strategies than current interventions. We also uncover several areas of potential for growth
364 in the precision medicine field, including prospectively designed interventions and clinical
365 trials incorporating the investigation of treatment response heterogeneity.

366 **AUTHOR CONTRIBUTIONS**

367 DB, RM, SLF, JSP, PWF, DT, JM, VM, and RJFL contributed to the conception and design
368 of the research questions. All authors contributed to the study screening and data extraction.
369 DT and JM did the quality assessment; DB, RM, VS, MN, SLF, MGF, JSP, MRL, DT, JM,
370 VM, and RJFL summarized and interpreted the data. DB, JM, and RJFL drafted the paper;
371 DT and VM revised it substantively. All authors edited the manuscript and approved the final
372 version.

373

374 **CONFLICTS OF INTEREST**

375 RWM and PWF are employees of the Novo Nordisk Foundation, a private philanthropic
376 enterprise foundation. The opinions expressed in this article do not necessarily reflect the
377 perspectives of the Novo Nordisk Foundation. VM has acted as consultant and speaker and
378 received research or educational grants from Novo Nordisk, MSD, Eli Lilly, Novartis,
379 Boehringer Ingelheim, Lifescan J & J, Sanofi-Aventis, Roche Diagnostics, Abbott, and
380 several Indian pharmaceutical companies, including USV, Dr. Reddy's Laboratories, and
381 Sun Pharma. None of the other authors have any conflicts of interest to declare.

382

383 **FUNDING**

384 The ADA/EASD Precision Diabetes Medicine Initiative, within which this work was
385 conducted, has received the following support: The Covidence license was funded by Lund
386 University (Sweden), for which technical support was provided by Maria Björklund and
387 Krister Aronsson (Faculty of Medicine Library, Lund University, Sweden). Administrative
388 support was provided by Lund University (Malmö, Sweden), the University of Chicago (IL,
389 USA), and the American Diabetes Association (Washington D.C., USA). The Novo Nordisk
390 Foundation (Hellerup, Denmark) provided grant support for in-person writing group meetings
391 (PI: L Phillipson, University of Chicago, IL). DB was supported through an Early Career
392 Research grant (ECR/2017/000640) from Science and Engineering Research Board

393 (SERB), India. JM was partially supported by funding from the American Diabetes
394 Association (7-21-JDFM-005) and the National Institutes of Health (P30 DK40561 and UG1
395 HD107691). RJFL received support through NNF18CC0034900; NNF20OC0059313
396 (Laureate Award); DNRF161 (Chair).

397 **REFERENCES**

- 398 1. Sun, H. *et al.* IDF Diabetes Atlas: Global, regional and country-level diabetes
399 prevalence estimates for 2021 and projections for 2045. *Diabetes Res Clin Pract* **183**,
400 109119 (2022).
- 401 2. Tuomi, T. *et al.* The many faces of diabetes: a disease with increasing heterogeneity.
402 *Lancet* **383**, 1084–94 (2014).
- 403 3. Knowler, W. C. *et al.* Reduction in the incidence of type 2 diabetes with lifestyle
404 intervention or metformin. *N Engl J Med* **346**, 393–403 (2002).
- 405 4. Tuomilehto, J. *et al.* Prevention of type 2 diabetes mellitus by changes in lifestyle
406 among subjects with impaired glucose tolerance. *N Engl J Med* **344**, 1343–50 (2001).
- 407 5. Pan, X. R. *et al.* Effects of diet and exercise in preventing NIDDM in people with
408 impaired glucose tolerance. The Da Qing IGT and Diabetes Study. *Diabetes Care* **20**,
409 537–44 (1997).
- 410 6. Ramachandran, A. *et al.* The Indian Diabetes Prevention Programme shows that
411 lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects
412 with impaired glucose tolerance (IDPP-1). *Diabetologia* **49**, 289–97 (2006).
- 413 7. Ling, W. *et al.* Global trend of diabetes mortality attributed to vascular complications,
414 2000–2016. *Cardiovasc Diabetol* **19**, (2020).
- 415 8. Chung, W. K. *et al.* Precision Medicine in Diabetes: A Consensus Report from the
416 American Diabetes Association (ADA) and the European Association for the Study of
417 Diabetes (EASD). *Diabetes Care* **43**, 1617–1635 (2020).
- 418 9. Xie, F., Chan, J. C. N. & Ma, R. C. W. Precision medicine in diabetes prevention,
419 classification and management. *Journal of Diabetes Investigation* vol. 9 998–1015
420 Preprint at <https://doi.org/10.1111/jdi.12830> (2018).
- 421 10. Mutie, P. M., Giordano, G. N. & Franks, P. W. Lifestyle precision medicine: The next
422 generation in type 2 diabetes prevention? *BMC Medicine* vol. 15 Preprint at
423 <https://doi.org/10.1186/s12916-017-0938-x> (2017).
- 424 11. Nolan, J. J. *et al.* ADA/EASD Precision Medicine in Diabetes Initiative: An
425 International Perspective and Future Vision for Precision Medicine in Diabetes.
426 *Diabetes Care* **45**, 261–266 (2022).
- 427 12. Covidence systematic review software. *Veritas Health Innovation, Melbourne,*
428 *Australia. Available at www.covidence.org.*
- 429 13. Barker, T. H. *et al.* The revised JBI critical appraisal tool for the assessment of risk of
430 bias for randomized controlled trials. *JBI Evid Synth* **21**, 494–506 (2023).
- 431 14. Sherifali, D. *et al.* Methods. *Can J Diabetes* **42**, S6–S9 (2018).
- 432 15. Gong, Q. *et al.* Efficacy of lifestyle intervention in adults with impaired glucose
433 tolerance with and without impaired fasting plasma glucose: A post hoc analysis of Da
434 Qing Diabetes Prevention Outcome Study. *Diabetes Obes Metab* **23**, 2385–2394
435 (2021).
- 436 16. Weber, M. B. *et al.* The Stepwise Approach to Diabetes Prevention: Results From the
437 D-CLIP Randomized Controlled Trial. *Diabetes Care* **39**, 1760–7 (2016).

- 438 17. Aekplakorn, W. *et al.* Evaluation of a Community-Based Diabetes Prevention Program
439 in Thailand: A Cluster Randomized Controlled Trial. *J Prim Care Community Health*
440 **10**, 2150132719847374 (2019).
- 441 18. Sakane, N. *et al.* Prevention of type 2 diabetes in a primary healthcare setting: three-
442 year results of lifestyle intervention in Japanese subjects with impaired glucose
443 tolerance. *BMC Public Health* **11**, 40 (2011).
- 444 19. Wagner, R. *et al.* Pathophysiology-based subphenotyping of individuals at elevated
445 risk for type 2 diabetes. *Nat Med* **27**, 49–57 (2021).
- 446 20. Ben-Yacov, O. *et al.* Personalized Postprandial Glucose Response-Targeting Diet
447 Versus Mediterranean Diet for Glycemic Control in Prediabetes. *Diabetes Care* **44**,
448 1980–1991 (2021).
- 449 21. Berry, S. E. *et al.* Human postprandial responses to food and potential for precision
450 nutrition. *Nat Med* **26**, 964–973 (2020).
- 451 22. Zeevi, D. *et al.* Personalized Nutrition by Prediction of Glycemic Responses. *Cell* **163**,
452 1079–1094 (2015).
- 453 23. Delgado-Lista, J. *et al.* CORonary Diet Intervention with Olive oil and cardiovascular
454 PREvention study (the CORDIOPREV study): Rationale, methods, and baseline
455 characteristics: A clinical trial comparing the efficacy of a Mediterranean diet rich in
456 olive oil versus a low-fat diet on cardiovascular disease in coronary patients. *Am*
457 *Heart J* **177**, 42–50 (2016).
- 458 24. Jimenez-Lucena, R. *et al.* MiRNAs profile as biomarkers of nutritional therapy for the
459 prevention of type 2 diabetes mellitus: From the CORDIOPREV study. *Clin Nutr* **40**,
460 1028–1038 (2021).
- 461 25. Estruch, R. *et al.* Primary Prevention of Cardiovascular Disease with a Mediterranean
462 Diet Supplemented with Extra-Virgin Olive Oil or Nuts. *N Engl J Med* **378**, e34 (2018).
- 463 26. Ruiz-Canela, M. *et al.* Plasma branched chain/aromatic amino acids, enriched
464 Mediterranean diet and risk of type 2 diabetes: case-cohort study within the
465 PREDIMED Trial. *Diabetologia* **61**, 1560–1571 (2018).
- 466 27. Corella, D. *et al.* CLOCK gene variation is associated with incidence of type-2
467 diabetes and cardiovascular diseases in type-2 diabetic subjects: dietary modulation
468 in the PREDIMED randomized trial. *Cardiovasc Diabetol* **15**, 4 (2016).
- 469 28. Ibarrola-Jurado, N., Salas-Salvadó, J., Martínez-González, M. A. & Bulló, M. Dietary
470 phylloquinone intake and risk of type 2 diabetes in elderly subjects at high risk of
471 cardiovascular disease. *Am J Clin Nutr* **96**, 1113–8 (2012).
- 472 29. Liu, X. *et al.* High plasma glutamate and low glutamine-to-glutamate ratio are
473 associated with type 2 diabetes: Case-cohort study within the PREDIMED trial. *Nutr*
474 *Metab Cardiovasc Dis* **29**, 1040–1049 (2019).
- 475 30. Salas-Salvadó, J. *et al.* Prevention of diabetes with Mediterranean diets: a subgroup
476 analysis of a randomized trial. *Ann Intern Med* **160**, 1–10 (2014).
- 477 31. Salas-Salvadó, J. *et al.* Reduction in the incidence of type 2 diabetes with the
478 Mediterranean diet: results of the PREDIMED-Reus nutrition intervention randomized
479 trial. *Diabetes Care* **34**, 14–9 (2011).

- 480 32. Shahbazi, S. & Vahdat Shariatpanahi, Z. Prevention of type 2 diabetes mellitus by
481 changes in diet among subjects with abnormal glucose metabolism: a randomized
482 clinical trial. *Int J Diabetes Dev Ctries* **38**, 69–74 (2018).
- 483 33. Tinker, L. F. *et al.* Low-fat dietary pattern and risk of treated diabetes mellitus in
484 postmenopausal women: the Women’s Health Initiative randomized controlled dietary
485 modification trial. *Arch Intern Med* **168**, 1500–11 (2008).
- 486 34. Howard, B. V. *et al.* A Low-Fat Dietary Pattern and Diabetes: A Secondary Analysis
487 From the Women’s Health Initiative Dietary Modification Trial. *Diabetes Care* **41**, 680–
488 687 (2018).
- 489 35. The alpha-tocopherol, beta-carotene lung cancer prevention study: design, methods,
490 participant characteristics, and compliance. The ATBC Cancer Prevention Study
491 Group. *Ann Epidemiol* **4**, 1–10 (1994).
- 492 36. Kataja-Tuomola, M. *et al.* Effect of alpha-tocopherol and beta-carotene
493 supplementation on the incidence of type 2 diabetes. *Diabetologia* **51**, 47–53 (2008).
- 494 37. Pittas, A. G. *et al.* Vitamin D Supplementation and Prevention of Type 2 Diabetes. *N*
495 *Engl J Med* **381**, 520–530 (2019).
- 496 38. Song, Y., Cook, N. R., Albert, C. M., Van Denburgh, M. & Manson, J. E. Effect of
497 homocysteine-lowering treatment with folic Acid and B vitamins on risk of type 2
498 diabetes in women: a randomized, controlled trial. *Diabetes* **58**, 1921–8 (2009).
- 499 39. Song, Y., Cook, N. R., Albert, C. M., Van Denburgh, M. & Manson, J. E. Effects of
500 vitamins C and E and beta-carotene on the risk of type 2 diabetes in women at high
501 risk of cardiovascular disease: a randomized controlled trial. *Am J Clin Nutr* **90**, 429–
502 37 (2009).
- 503 40. Lee, I.-M. *et al.* Vitamin E in the primary prevention of cardiovascular disease and
504 cancer: the Women’s Health Study: a randomized controlled trial. *JAMA* **294**, 56–65
505 (2005).
- 506 41. Liu, S. *et al.* Vitamin E and risk of type 2 diabetes in the women’s health study
507 randomized controlled trial. *Diabetes* **55**, 2856–62 (2006).
- 508 42. Chae, J. S. *et al.* Supervised exercise program, BMI, and risk of type 2 diabetes in
509 subjects with normal or impaired fasting glucose. *Diabetes Care* **35**, 1680–5 (2012).
- 510 43. Li, G. *et al.* Cardiovascular mortality, all-cause mortality, and diabetes incidence after
511 lifestyle intervention for people with impaired glucose tolerance in the Da Qing
512 Diabetes Prevention Study: a 23-year follow-up study. *Lancet Diabetes Endocrinol* **2**,
513 474–80 (2014).
- 514 44. Li, G. *et al.* Effects of insulin resistance and insulin secretion on the efficacy of
515 interventions to retard development of type 2 diabetes mellitus: the DA Qing IGT and
516 Diabetes Study. *Diabetes Res Clin Pract* **58**, 193–200 (2002).
- 517 45. Costa, B. *et al.* Delaying progression to type 2 diabetes among high-risk Spanish
518 individuals is feasible in real-life primary healthcare settings using intensive lifestyle
519 intervention. *Diabetologia* **55**, 1319–28 (2012).
- 520 46. O’Brien, M. J., Whitaker, R. C., Yu, D. & Ackermann, R. T. The comparative efficacy
521 of lifestyle intervention and metformin by educational attainment in the Diabetes
522 Prevention Program. *Prev Med (Baltim)* **77**, 125–30 (2015).

- 523 47. Kriska, A. M. *et al.* The Impact of Physical Activity on the Prevention of Type 2
524 Diabetes: Evidence and Lessons Learned From the Diabetes Prevention Program, a
525 Long-Standing Clinical Trial Incorporating Subjective and Objective Activity Measures.
526 *Diabetes Care* **44**, 43–49 (2021).
- 527 48. Allaire, B. T. *et al.* Diet quality, weight loss, and diabetes incidence in the Diabetes
528 Prevention Program (DPP). *BMC Nutr* **6**, 74 (2020).
- 529 49. Billings, L. K. *et al.* Variation in Maturity-Onset Diabetes of the Young Genes Influence
530 Response to Interventions for Diabetes Prevention. *J Clin Endocrinol Metab* **102**,
531 2678–2689 (2017).
- 532 50. Crandall, J. P. *et al.* Alcohol consumption and diabetes risk in the Diabetes Prevention
533 Program. *Am J Clin Nutr* **90**, 595–601 (2009).
- 534 51. Maruthur, N. M. *et al.* Early response to preventive strategies in the Diabetes
535 Prevention Program. *J Gen Intern Med* **28**, 1629–36 (2013).
- 536 52. Florez, J. C. *et al.* TCF7L2 polymorphisms and progression to diabetes in the
537 Diabetes Prevention Program. *N Engl J Med* **355**, 241–50 (2006).
- 538 53. Moore, A. F. *et al.* The association of ENPP1 K121Q with diabetes incidence is
539 abolished by lifestyle modification in the diabetes prevention program. *J Clin*
540 *Endocrinol Metab* **94**, 449–55 (2009).
- 541 54. Florez, J. C. *et al.* Testing of diabetes-associated WFS1 polymorphisms in the
542 Diabetes Prevention Program. *Diabetologia* **51**, 451–7 (2008).
- 543 55. Pan, Q. *et al.* Variation at the melanocortin 4 receptor gene and response to weight-
544 loss interventions in the diabetes prevention program. *Obesity (Silver Spring)* **21**,
545 E520-6 (2013).
- 546 56. Diabetes Prevention Program Research Group *et al.* The influence of age on the
547 effects of lifestyle modification and metformin in prevention of diabetes. *J Gerontol A*
548 *Biol Sci Med Sci* **61**, 1075–81 (2006).
- 549 57. Diabetes Prevention Program Research Group *et al.* 10-year follow-up of diabetes
550 incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
551 *Lancet* **374**, 1677–86 (2009).
- 552 58. Raghavan, S. *et al.* Interaction of diabetes genetic risk and successful lifestyle
553 modification in the Diabetes Prevention Programme. *Diabetes Obes Metab* **23**, 1030–
554 1040 (2021).
- 555 59. Herman, W. H. *et al.* Impact of Lifestyle and Metformin Interventions on the Risk of
556 Progression to Diabetes and Regression to Normal Glucose Regulation in Overweight
557 or Obese People With Impaired Glucose Regulation. *Diabetes Care* **40**, 1668–1677
558 (2017).
- 559 60. Hivert, M.-F. *et al.* Updated genetic score based on 34 confirmed type 2 diabetes Loci
560 is associated with diabetes incidence and regression to normoglycemia in the
561 diabetes prevention program. *Diabetes* **60**, 1340–8 (2011).
- 562 61. Jablonski, K. A. *et al.* Common variants in 40 genes assessed for diabetes incidence
563 and response to metformin and lifestyle intervention in the diabetes prevention
564 program. *Diabetes* **59**, 2672–81 (2010).
- 565 62. Fujimoto, W. Y. *et al.* Body size and shape changes and the risk of diabetes in the
566 diabetes prevention program. *Diabetes* **56**, 1680–5 (2007).

- 567 63. Sussman, J. B., Kent, D. M., Nelson, J. P. & Hayward, R. A. Improving diabetes
568 prevention with benefit based tailored treatment: risk based reanalysis of Diabetes
569 Prevention Program. *BMJ* **350**, h454 (2015).
- 570 64. Diabetes Prevention Program (DPP) Research Group *et al.* Factors affecting the
571 decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study
572 (DPPOS). *Diabetes* **64**, 989–98 (2015).
- 573 65. Penn, L. *et al.* Prevention of type 2 diabetes in adults with impaired glucose tolerance:
574 the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. *BMC Public*
575 *Health* **9**, 342 (2009).
- 576 66. Penn, L. *et al.* Importance of weight loss maintenance and risk prediction in the
577 prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT.
578 *PLoS One* **8**, e57143 (2013).
- 579 67. Mager, U. *et al.* Association of the Leu72Met polymorphism of the ghrelin gene with
580 the risk of Type 2 diabetes in subjects with impaired glucose tolerance in the Finnish
581 Diabetes Prevention Study. *Diabet Med* **23**, 685–9 (2006).
- 582 68. Laaksonen, D. E. *et al.* Physical activity, diet, and incident diabetes in relation to an
583 ADRA2B polymorphism. *Med Sci Sports Exerc* **39**, 227–32 (2007).
- 584 69. Herder, C. *et al.* Systemic immune mediators and lifestyle changes in the prevention
585 of type 2 diabetes: results from the Finnish Diabetes Prevention Study. *Diabetes* **55**,
586 2340–6 (2006).
- 587 70. Kilpeläinen, T. O. *et al.* Interaction of single nucleotide polymorphisms in ADRB2,
588 ADRB3, TNF, IL6, IGF1R, LIPC, LEPR, and GHRL with physical activity on the risk of
589 type 2 diabetes mellitus and changes in characteristics of the metabolic syndrome:
590 The Finnish Diabetes Prevention Study. *Metabolism* **57**, 428–36 (2008).
- 591 71. Tuomilehto, H. *et al.* Sleep duration, lifestyle intervention, and incidence of type 2
592 diabetes in impaired glucose tolerance: The Finnish Diabetes Prevention Study.
593 *Diabetes Care* **32**, 1965–71 (2009).
- 594 72. Kilpeläinen, T. O. *et al.* Physical activity modifies the effect of SNPs in the SLC2A2
595 (GLUT2) and ABCC8 (SUR1) genes on the risk of developing type 2 diabetes. *Physiol*
596 *Genomics* **31**, 264–72 (2007).
- 597 73. Uusitupa, M. I. *et al.* Impact of positive family history and genetic risk variants on the
598 incidence of diabetes: the Finnish Diabetes Prevention Study. *Diabetes Care* **34**, 418–
599 23 (2011).
- 600 74. Lindi, V. I. *et al.* Association of the Pro12Ala polymorphism in the PPAR-gamma2
601 gene with 3-year incidence of type 2 diabetes and body weight change in the Finnish
602 Diabetes Prevention Study. *Diabetes* **51**, 2581–6 (2002).
- 603 75. Laukkanen, O. *et al.* Common polymorphisms in the genes regulating the early insulin
604 signalling pathway: effects on weight change and the conversion from impaired
605 glucose tolerance to Type 2 diabetes. The Finnish Diabetes Prevention Study.
606 *Diabetologia* **47**, 871–7 (2004).
- 607 76. Lindström, J. *et al.* Determinants for the effectiveness of lifestyle intervention in the
608 Finnish Diabetes Prevention Study. *Diabetes Care* **31**, 857–62 (2008).
- 609 77. Laaksonen, D. E. *et al.* Physical activity in the prevention of type 2 diabetes: the
610 Finnish diabetes prevention study. *Diabetes* **54**, 158–65 (2005).

- 611 78. Siitonen, N. *et al.* Association between a deletion/insertion polymorphism in the
612 alpha2B-adrenergic receptor gene and insulin secretion and Type 2 diabetes. The
613 Finnish Diabetes Prevention Study. *Diabetologia* **47**, 1416–24 (2004).
- 614 79. Laukkanen, O. *et al.* Polymorphisms in the SLC2A2 (GLUT2) gene are associated
615 with the conversion from impaired glucose tolerance to type 2 diabetes: the Finnish
616 Diabetes Prevention Study. *Diabetes* **54**, 2256–60 (2005).
- 617 80. Kilpeläinen, T. O. *et al.* SNPs in PPARG associate with type 2 diabetes and interact
618 with physical activity. *Med Sci Sports Exerc* **40**, 25–33 (2008).
- 619 81. Todorova, B. *et al.* The G-250A promoter polymorphism of the hepatic lipase gene
620 predicts the conversion from impaired glucose tolerance to type 2 diabetes mellitus:
621 the Finnish Diabetes Prevention Study. *J Clin Endocrinol Metab* **89**, 2019–23 (2004).
- 622 82. Ramachandran, A. *et al.* Effectiveness of mobile phone messaging in prevention of
623 type 2 diabetes by lifestyle modification in men in India: a prospective, parallel-group,
624 randomised controlled trial. *Lancet Diabetes Endocrinol* **1**, 191–8 (2013).
- 625 83. Nanditha, A. *et al.* Impact of lifestyle intervention in primary prevention of Type 2
626 diabetes did not differ by baseline age and BMI among Asian-Indian people with
627 impaired glucose tolerance. *Diabet Med* **33**, 1700–1704 (2016).
- 628 84. Ramachandran, A., Arun, N., Shetty, A. S. & Snehalatha, C. Efficacy of primary
629 prevention interventions when fasting and postglucose dysglycemia coexist: analysis
630 of the Indian Diabetes Prevention Programmes (IDPP-1 and IDPP-2). *Diabetes Care*
631 **33**, 2164–8 (2010).
- 632 85. Ramachandran, A. *et al.* Pioglitazone does not enhance the effectiveness of lifestyle
633 modification in preventing conversion of impaired glucose tolerance to diabetes in
634 Asian Indians: results of the Indian Diabetes Prevention Programme-2 (IDPP-2).
635 *Diabetologia* **52**, 1019–26 (2009).
- 636 86. Sakane, N. *et al.* Effect of baseline HbA1c level on the development of diabetes by
637 lifestyle intervention in primary healthcare settings: insights from subanalysis of the
638 Japan Diabetes Prevention Program. *BMJ Open Diabetes Res Care* **2**, e000003
639 (2014).
- 640 87. Sathish, T. *et al.* Cluster randomised controlled trial of a peer-led lifestyle intervention
641 program: study protocol for the Kerala diabetes prevention program. *BMC Public*
642 *Health* **13**, 1035 (2013).
- 643 88. Thankappan, K. R. *et al.* A peer-support lifestyle intervention for preventing type 2
644 diabetes in India: A cluster-randomized controlled trial of the Kerala Diabetes
645 Prevention Program. *PLoS Med* **15**, e1002575 (2018).
- 646 89. Kosaka, K., Noda, M. & Kuzuya, T. Prevention of type 2 diabetes by lifestyle
647 intervention: a Japanese trial in IGT males. *Diabetes Res Clin Pract* **67**, 152–62
648 (2005).
- 649 90. Gray, L. J. *et al.* Let's prevent diabetes: study protocol for a cluster randomised
650 controlled trial of an educational intervention in a multi-ethnic UK population with
651 screen detected impaired glucose regulation. *Cardiovasc Diabetol* **11**, 56 (2012).
- 652 91. Davies, M. J. *et al.* A community based primary prevention programme for type 2
653 diabetes integrating identification and lifestyle intervention for prevention: the Let's
654 Prevent Diabetes cluster randomised controlled trial. *Prev Med (Baltim)* **84**, 48–56
655 (2016).

- 656 92. Davey Smith, G. *et al.* Incidence of type 2 diabetes in the randomized multiple risk
657 factor intervention trial. *Ann Intern Med* **142**, 313–22 (2005).
- 658 93. Nanditha, A. *et al.* A pragmatic and scalable strategy using mobile technology to
659 promote sustained lifestyle changes to prevent type 2 diabetes in India and the UK: a
660 randomised controlled trial. *Diabetologia* **63**, 486–496 (2020).
- 661 94. Saaristo, T. *et al.* Lifestyle intervention for prevention of type 2 diabetes in primary
662 health care: one-year follow-up of the Finnish National Diabetes Prevention Program
663 (FIN-D2D). *Diabetes Care* **33**, 2146–51 (2010).
- 664 95. Rautio, N. *et al.* Do statins interfere with lifestyle intervention in the prevention of
665 diabetes in primary healthcare? One-year follow-up of the FIN-D2D project. *BMJ*
666 *Open* **2**, (2012).
- 667 96. Rintamäki, R. *et al.* Long-term outcomes of lifestyle intervention to prevent type 2
668 diabetes in people at high risk in primary health care. *Prim Care Diabetes* **15**, 444–
669 450 (2021).
- 670 97. Rautio, N. *et al.* Family history of diabetes and effectiveness of lifestyle counselling on
671 the cardio-metabolic risk profile in individuals at high risk of Type 2 diabetes: 1-year
672 follow-up of the FIN-D2D project. *Diabet Med* **29**, 207–11 (2012).
- 673 98. Rautio, N. *et al.* Socioeconomic position and effectiveness of lifestyle intervention in
674 prevention of type 2 diabetes: one-year follow-up of the FIN-D2D project. *Scand J*
675 *Public Health* **39**, 561–70 (2011).
- 676 99. Raghuram, N. *et al.* Effectiveness of a Yoga-Based Lifestyle Protocol (YLP) in
677 Preventing Diabetes in a High-Risk Indian Cohort: A Multicenter Cluster-Randomized
678 Controlled Trial (NMB-Trial). *Front Endocrinol (Lausanne)* **12**, 664657 (2021).
- 679 100. Sampson, M. *et al.* Lifestyle Intervention With or Without Lay Volunteers to Prevent
680 Type 2 Diabetes in People With Impaired Fasting Glucose and/or Nondiabetic
681 Hyperglycemia: A Randomized Clinical Trial. *JAMA Intern Med* **181**, 168–178 (2021).
- 682 101. Sanchez, A., Silvestre, C., Campo, N., Grandes, G. & PredDE Group. Effective
683 translation of a type-2 diabetes primary prevention programme into routine primary
684 care: The PreDE cluster randomised clinical trial. *Diabetes Res Clin Pract* **139**, 32–42
685 (2018).
- 686 102. Harati, H. *et al.* Reduction in incidence of type 2 diabetes by lifestyle intervention in a
687 middle eastern community. *Am J Prev Med* **38**, 628-636.e1 (2010).
- 688 103. Derakhshan, A. *et al.* Sex specific incidence rates of type 2 diabetes and its risk
689 factors over 9 years of follow-up: Tehran Lipid and Glucose Study. *PLoS One* **9**,
690 e102563 (2014).
- 691 104. Norberg, M., Wall, S., Boman, K. & Weinehall, L. The Västerbotten Intervention
692 Programme: background, design and implications. *Glob Health Action* **3**, (2010).
- 693 105. Long, G. H. *et al.* Healthy behaviours and 10-year incidence of diabetes: a population
694 cohort study. *Prev Med (Baltim)* **71**, 121–7 (2015).
- 695 106. Saito, T. *et al.* Lifestyle modification and prevention of type 2 diabetes in overweight
696 Japanese with impaired fasting glucose levels: a randomized controlled trial. *Arch*
697 *Intern Med* **171**, 1352–60 (2011).

698

Table 1: Description of study population and study design of the included trials grouped according to the type of intervention

Trial/Study Name	Study Population		Study Design					Main Trial Info PMIDs	Included Studies (PMDIs)
	Country	Total Enrolled; Inclusion Criteria	Baseline Enrollment Years	Intervention Design	Active Intervention Duration	Intervention(s)	Comparator/ Control Intervention		
DIETARY PATTERN INTERVENTIONS									
CORonary Diet Intervention with Olive oil and cardiovascular PREvention study (CORDIOPREV)	Spain	N=1,002; Prevalent heart disease	2009/12	Randomized, parallel arm	Median 7 years	Mediterranean dietary pattern	AHA low-fat pattern (<30% kcal)	27297848 ²³	32723508 ²⁴
Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts (PREDIMED)	Spain	N=7,447; High cardiovascular risk	2003/09	Randomized, parallel arm	4.8 years	(i) Mediterranean pattern + extra-virgin olive oil; (ii) Mediterranean pattern + mixed nuts	Low-fat pattern	29897866 ²⁵	29663011 ²⁶ , 26739996 ²⁷ , 23034962 ²⁸ , 31377179 ²⁹ , 24573661 ³⁰ , 20929998 ³¹
Shahbazi et al (2018)	Iran	N=336; Prediabetes	2012	Randomized, parallel arm	2 years	(i) High fat diet from olive oil (45% kcal); (ii) Normal fat diet (30% kcal)	Standard low-fat diet (<30% kcal)	DOI 10.1007/s13410-017-0548-3	DOI 10.1007/s13410-017-0548-3 ³²
Women's Health Initiative Dietary Modification Trial (WHI-DM)	US	N=48,835; Healthy postmenopausal women	1993/98	Randomized, parallel arm	Mean 8.1 years	Low-fat (20% kcal) healthy pattern	Provided with healthy diet materials at baseline	18663162 ³³	29282203 ³⁴
DIETARY SUPPLEMENT INTERVENTIONS									
Alpha-Tocopherol, Beta-Carotene Lung Cancer Prevention Study (ATBC)	Finland	N=29,133; Men, smokers	1985/88	Randomized, parallel arm	Median 6.1 years	2x2 factorial: (i) alpha-tocopherol (50mg/d), (ii) beta-carotene (20mg/d)	Placebo	8205268 ³⁵	17994292 ³⁶
Vitamin D and Type 2 Diabetes Trial (D2d)	US	N=2,423; Prediabetes	2013/17	Randomized, parallel arm	Median 2.5 years	Vitamin D supplementation (4000 IU/day)	Placebo	31173679 ³⁷	31173679 ³⁷
Women's Antioxidant and Folic Acid Cardiovascular Study (WAFACS)	US	N=5,442; Women with cardiovascular disease	1998	Randomized, parallel arm	Median 7.3 years	Folic acid (2.5 mg/d), vitamin B6 (50 mg/d), and vitamin B12 (1 mg/d) combined supplementation	Placebo	19491213 ³⁸	19491213 ³⁸

Women's Antioxidant Cardiovascular Study (WACS)	US	N=8,171; Women with cardiovascular disease	1995/96	Randomized, parallel arm	Median 9.2 years	2x2x2 factorial: (i) vitamin C (500 mg/d), (ii) vitamin E (600 IU/d), (iii) beta-carotene (50 mg/eod) supplementation	Placebo	19491386 ³⁹	19491386 ³⁹
Women's Health Study (WHS)	US	N=39,876; Healthy women	1992/95	Randomized, parallel arm	10.1 years	2x2 Factorial, every other day: Aspirin (100 mg); (ii) Vitamin E supplementation (600 IU)	Placebo	15998891 ⁴⁰	17003353 ⁴¹
LIFESTYLE PROGRAMS									
Chae et al (2012)	South Korea	N=7,233; General population	2007/11	Non-randomized, parallel arm	6 months	Physical activity program	Usual care	22688549 ⁴²	22688549 ⁴²
Da Qing IGT and Diabetes Study	China	N=577; Prediabetes	1986	Cluster-randomized trial	6 years	(i) Diet: Low-calorie, low-fat (25-30% kcal) healthy pattern; (ii) Increase exercise; (iii) Diet + Exercise	Provided with diabetes education materials at baseline	9096977 ⁵	24731674 ⁴³ , 34212465 ¹⁵ , 12413779 ⁴⁴
Diabetes Community Lifestyle Improvement Program (D-CLIP)	India	N=578; Prediabetes	2009/12	Randomized, parallel arm	3 years	Lifestyle diabetes prevention program + Metformin	Lifestyle diabetes prevention program at baseline	27504014 ¹⁶	27504014 ¹⁶
Diabetes in Europe—Prevention using Lifestyle, Physical Activity and Nutritional - Catalonia (DE-PLAN-CAT)	Spain	N=544; Prediabetes	2006	Non-randomized, parallel arm	4 years	Lifestyle weight loss and diabetes prevention program	Provided with diabetes education materials at baseline	22322921 ⁴⁵	22322921 ⁴⁵
Diabetes Prevention Program (DPP)	US	N=3,234; Prediabetes	1996/99	Randomized, parallel arm	Mean 2.8 years	(i) Lifestyle weight loss and diabetes prevention program; (ii) Metformin	Usual care + placebo	11832527 ³	26024851 ⁴⁶ , 33444158 ⁴⁷ , 33317629 ⁴⁸ , 28453780 ⁴⁹ , 19640960 ⁵⁰ , 23860722 ⁵¹ , 16855264 ⁵²

									19017751 ⁵³ , 18060660 ⁵⁴ , 11832527 ³ , 23512951 ⁵⁵ , 17077202 ⁵⁶ , 19878986 ⁵⁷ , 33394545 ⁵⁸ , 29021207 ⁵⁹ , 21378175 ⁶⁰ , 20682687 ⁶¹ , 17363740 ⁶² , 25697494 ⁶³ , 25277389 ⁶⁴
EDIPS-Newcastle	UK	N=102; Prediabetes		Randomized, parallel arm	5 years	Lifestyle diabetes prevention program	Usual care	19758428 ⁶⁵	23451166 ⁶⁶
Finnish Diabetes Prevention Study (DPS)	Finland	N=522; Prediabetes	1993/98	Randomized, parallel arm	Mean 3.2 years	Lifestyle and weight loss diabetes prevention program	Provided with diabetes education materials at baseline	11333990 ⁴	16759313 ⁶⁷ , 17277585 ⁶⁸ , 16873699 ⁶⁹ , 18249219 ⁷⁰ , 19651919 ⁷¹ , 17636114 ⁷² , 11333990 ⁴ , 20980412 ⁷³ , 12145174 ⁷⁴ , 15127203 ⁷⁵ , 18252900 ⁷⁶ , 15616024 ⁷⁷ , 15309292 ⁷⁸ , 15983230 ⁷⁹ , 18091023 ⁸⁰ , 15126514 ⁸¹
Indian Diabetes Prevention Program 2013 (IDPP-2013)	India	N=537; Men with prediabetes	2009	Randomized, parallel arm	24 months	SMS-delivered lifestyle diabetes prevention education	Provided with diabetes education materials at baseline	24622367 ⁸²	26773871 ⁸³ , 16391903 ⁶
Indian Diabetes Prevention Programme (IDPP-1)	India	N=531; Prediabetes	2001/02	Randomized, parallel arm	3 years	(i) Lifestyle diabetes prevention program; (ii) Metformin; (iii) Lifestyle + Metformin	Usual care	16391903 ⁶	16391903 ⁶ , 20519663 ⁸⁴ , 26773871 ⁸³
Indian Diabetes Prevention Programme	India	N=407; Prediabetes	2003/05	Randomized, parallel arm	3 years	Lifestyle diabetes prevention program	Lifestyle diabetes	19277602 ⁸⁵	20519663 ⁸⁴

(IDPP-2)						+ Pioglitazone	prevention program + Placebo		
Japan Diabetes Prevention Program (Japan DPP)	Japan	N=304; Prediabetes	1999/02	Randomized, parallel arm	3 years	Lifestyle weight loss and diabetes prevention program	Provided with diabetes education materials at baseline	25452854 ⁸⁶	25452854 ⁸⁶ , 21235825 ¹⁸
Kerala Diabetes Prevention Program (K-DPP)	India	N=1,007; Prediabetes, rural	2013	Cluster-randomized trial	12 months	Peer-led lifestyle diabetes prevention program	Provided with diabetes education materials at baseline	24180316 ⁸⁷	29874236 ⁸⁸
Kosaka et al (2004)	Japan	N=458; Men with prediabetes	1990/92	Randomized, parallel arm	4 years	Lifestyle weight loss and diabetes prevention program	Lifestyle weight loss and diabetes prevention information only	15649575 ⁸⁹	15649575 ⁸⁹
Let's Prevent Diabetes	UK	N=880; Prediabetes	2009/11	Cluster-randomized trial	36 months	Lifestyle diabetes prevention program	Provided with diabetes education materials at baseline	22607160 ⁹⁰	26740346 ⁹¹
Multiple Risk Factor Intervention Trial (MRFIT)	US	N=12,866; Men with high cardiovascular risk	1973/76	Randomized, parallel arm	6 years	Lifestyle modifications for heart disease prevention	Usual care	15738450 ⁹²	15738450 ⁹²
Nanditha, et al (2020)	India, UK	N=2,062; Prediabetes	2012/17	Randomized, parallel arm	24 months	SMS-delivered lifestyle diabetes prevention education	Provided with diabetes education materials at baseline	31919539 ⁹³	31919539 ⁹³
National Program for the Prevention of Type 2 Diabetes (FIN-D2D)	Finland	N=2,798; Prediabetes	2004/07	Population-wide intervention	Mean 14 months	Lifestyle weight loss and diabetes prevention program	--	20664020 ⁹⁴	22983785 ⁹⁵ , 33771515 ⁹⁶ , 21781153 ⁹⁷ , 20664020 ⁹⁴ , 21622677 ⁹⁸
Niyantrita Madhmeha Bharata Abhiyaan (NMB-Trial)	India	N=4,450; Prediabetes	2017	Cluster-randomized trial	3 months	Yoga-based lifestyle diabetes prevention program	Presentation on lifestyle for diabetes prevention at baseline	34177805 ⁹⁹	34177805 ⁹⁹

Norfolk Diabetes Prevention Study (NDPS)	UK	N=1,028; Prediabetes	2011/18	Randomized, parallel arm	12-46 months	(i) Lifestyle diabetes prevention program; (ii) Lifestyle diabetes prevention program with peer support	Provided with diabetes education materials at baseline	33136119 ¹⁰⁰ ₀	33136119 ¹⁰ ₀
Prevention of Diabetes in Euskadi (PreDE)	Spain	N=1,088; Prediabetes	2011/13	Cluster-randomized trial	24 months	Lifestyle weight loss and diabetes prevention program	Usual care	29476888 ¹⁰¹	29476888 ¹⁰ ₁
Tehran Lipid and Glucose Study (TLGS)	Iran	N=10,368; General population	1999/01	Non-randomized, cluster	Mean 3.6 years	Lifestyle program for chronic disease prevention	Usual care	20494239 ¹⁰²	25029368 ¹⁰ _{3,1} 20494239 ¹⁰ ₂
Thai Diabetes Prevention Program (Thai DPP)	Thailand	N=1,903; Prediabetes	2013	Cluster-randomized trial	24 months	Lifestyle diabetes prevention program	Provided with diabetes education materials at baseline	31079517 ¹⁷	31079517 ¹⁷
Västerbotten Intervention Programme (VIP)	Sweden	N=113, 203; General population	1987-present	Population-wide intervention	Ongoing	Lifestyle CVD and diabetes prevention program	--	20339479 ¹⁰⁴	25532678 ¹⁰ ₅
Zensharen Study for Prevention of Lifestyle Diseases	Japan	N=641; Prediabetes	2004/06	Randomized, parallel arm	36 months	Lifestyle weight loss program + Frequent engagement	Lifestyle weight loss program + Minimal engagement	21824948 ¹⁰⁶	21824948 ¹⁰ ₆

Table 2: Efficacy of T2D preventive interventions according to sociodemographic effect modifiers

Modifier	T2D preventive strategies								
	Intensive Lifestyle intervention			Dietary intervention			Dietary Supplements		
	Number of Studies	Effect modification [#]	Certainty of evidence [*]	Number of Studies	Effect modification [#]	Certainty of evidence [*]	Number of Studies	Effect modification [#]	Certainty of evidence [*]
Age	12	Yes: 7 studies No: 5 studies	Grade D	3	No: 3 studies	Grade D	4	Yes: 1 study No: 3 studies	Grade D
Sex	16	Yes: 1 study No: 15 studies	Grade D	2	No: 2 studies	Grade D	1	Yes: 1 study	Grade D
Race/ethnicity	3	No: 3 studies	Grade D	1	No: 1 study	Grade D	1	No: 1 study	Grade D
Socioeconomic status/ Education	5	Yes: 1 study No: 4 studies	Grade D	-	-	-	-	-	-
Location	2	No: 2 studies	Grade D	-	-	-	1	No: 1 study	-

Table legend: Overview of the included studies investigating whether sociodemographic factors modify the response to T2D preventive intervention strategies. [#] Yes/ No corresponds to significant/ nonsignificant effect modification, as reported in the study. ^{*}Certainty of evidence denotes consistency, Grading based on Diabetes Canada scale A to D.

Table 3: Efficacy of T2D preventive interventions according to clinical effect modifiers

Modifier	T2D preventive strategies								
	Intensive Lifestyle intervention			Dietary intervention			Dietary Supplements		
	Number of Studies	Effect modification [#]	Certainty of evidence [*]	Number of Studies	Effect modification [#]	Certainty of evidence [*]	Number of Studies	Effect modification [#]	Certainty of evidence [*]
BMI	14	Yes: 5 studies No: 9 studies	Grade D	3	No: 3 studies	Grade D	4	Yes: 1 study No: 3 studies	Grade D
Prediabetes	18	Yes: 8 studies No: 10 studies	Grade D	1	No: 1 study	Grade D	1	No: 1 study	Grade D
Family history	3	Yes: 1 study No: 2 studies	Grade D	-	-		3	Yes: 2 studies No: 1 study	Grade D
Dyslipidemia/ medications	1	No: 1 study	Grade D	2	Yes: 2 studies	Grade D	2	Yes: 1 study No: 1 study	Grade D
Hypertension	-	-	-	2	Yes: 1 study No: 1 study	Grade D	2	No: 2 studies	Grade D
Metabolic syndrome	-	-	-	1	Yes: 1 study	Grade D	1	No: 1 study	Grade D
Menopausal status, HRT use	-	-	-	-	-	-	3	No: 3 studies	Grade D

Table legend: Overview of the included studies investigating whether clinical factors modify the response to T2D preventive intervention strategies. [#] Yes/ No corresponds to significant/ nonsignificant effect modification, as reported in the study. ^{*}Certainty of evidence denotes consistency, Grading based on Diabetes Canada scale A to D.

Table 4: Efficacy of T2D preventive interventions according to behavioral effect modifiers

Modifier	T2D preventive strategies								
	Intensive Lifestyle intervention			Dietary intervention			Dietary Supplements		
	Number of Studies	Effect modification [#]	Certainty of evidence [*]	Number of Studies	Effect modification [#]	Certainty of evidence [*]	Number of Studies	Effect modification [#]	Certainty of evidence [*]
Smoking	2	Yes: 2 studies	Grade D	1	No: 1 study	Grade D	3	No: 3 studies	Grade D
Physical activity	3	Yes: 2 studies No: 1 study	Grade D	1	No: 1 study	Grade D	3	No: 3 studies	Grade D
Alcohol intake	1	Yes: 1 study	Grade D	-	-	-	3	No: 3 studies	Grade D
Diet and supplements	-	-	-	2	No: 2 studies	Grade D	6	No: 6 studies	Grade D

Table legend: Overview of the included studies investigating whether behavioral factors at baseline modify the response to T2D preventive intervention strategies. [#] Yes/ No corresponds to significant/ nonsignificant effect modification, as reported in the study. ^{*}Certainty of evidence denotes consistency, Grading based on Diabetes Canada scale A to D.

Table 5: Efficacy of T2D preventive interventions according to molecular effect modifiers

	T2D preventive strategies					
	Intensive Lifestyle intervention			Dietary intervention		
Modifier	Number of Studies	Effect modification [#]	Certainty of evidence [*]	Number of Studies	Effect modification [#]	Certainty of evidence [*]
T2D single SNPs	16	Yes: 10 studies No: 6 studies	Grade D	1	Yes: 1 study	Grade D
Diabetes polygenic score	5	Yes: 1 study No: 4 studies	Grade D	-	-	-
Metabolites/ miRNA	-	-	-	3	Yes: 3 studies	Grade D

Table legend: Overview of the included studies investigating whether genetic and molecular factors at baseline modify the response to T2D preventive intervention strategies. [#] Yes/ No corresponds to significant/ nonsignificant effect modification, as reported in the study. ^{*}Certainty of evidence denotes consistency, Grading based on Diabetes Canada scale A to D.

Figure 1: Study Screening Attrition Diagram




Figure Legend: Stepwise screening stages adapted for selecting the studies of interest using Covidence software. Screening at all stages was done by two independent reviewers and conflicts resolved by a third reviewer.

Figure 2: Potential effect modifiers of lifestyle, diet, and diet supplements intervention on the incidence of T2D




Figure Legend: General overview of potential effect modifiers of lifestyle (Panel A), dietary (Panel B), and supplement (Panel C) interventions on the incidence of type 2 diabetes. The Y axes indicate potential effect modifiers, and the X axes illustrate the total number of trial participants included in the studies investigating each modifier. The proportion of grey or white in each bar indicates the number of trial participants included in the studies where there was (grey) or was not (white) an effect by the effect modifier. Caution is warranted because whether an effect modifier did (or did not) have an effect is based on statistical significance from the publication's summary statistics, and it is improbable that the effect modifier strictly did (or did not) have an effect on every participant included in that publication. The number of trials and trial participants are plotted because some trials (eg DPP) had multiple studies published using the same participants such that the participant number would be heavily skewed. There was no instance where the same trial had multiple published studies evaluating the same effect modifier showing different results (e.g., there was no difference between sexes on the PREDIMED trial's effect on T2D incidence in their primary versus subgroup studies/publications). The number at the end of each bar represents the number of trials for each potential effect modifier. *indicates an exception for genetics because the effect modifiers (SNPs or GRS) were all uniquely distinct but are presented together under the categories of "SNP" or "GRS" here.